Mammoth Biosciences IPO
Mammoth Biosciences is a biotechnology company that develops CRISPR-based diagnostic and therapeutic platforms. The company focuses on creating next-generation gene editing tools and diagnostic tests using its proprietary CRISPR technology, with applications in healthcare, agriculture, and industrial biotechnology. Investors are interested in Mammoth Biosciences due to the transformative potential of CRISPR technology and the company's innovative approach to gene editing applications.
Key Facts
| Industry | Biotechnology |
| Founded | 2017 |
| Headquarters | South San Francisco, CA |
| Employees | ~150 |
| Website | mammothbiosciences.com |
| Funding | Series C funding. Total raised: ~$195M |
About Mammoth Biosciences
Mammoth Biosciences is a CRISPR-based biotechnology company that develops next-generation gene editing and biosensing technologies. Founded by pioneers in CRISPR research, including Nobel laureate Jennifer Doudna, the company focuses on discovering and developing novel CRISPR systems beyond the commonly used Cas9 protein. Mammoth's proprietary CRISPR systems enable more precise gene editing and innovative diagnostic applications.
The company's technology platform spans both therapeutic applications and diagnostic tools, with particular emphasis on developing point-of-care diagnostic tests that can detect pathogens, including COVID-19, with high accuracy and speed. Mammoth's approach to CRISPR goes beyond gene editing to include using CRISPR proteins as biosensors, potentially revolutionizing how diseases are diagnosed. The company represents the next wave of CRISPR innovation, moving beyond the foundational Cas9 system to explore the vast diversity of CRISPR proteins found in nature.
IPO Status
Mammoth Biosciences has not announced any plans for an initial public offering. The company has raised substantial venture capital funding from prominent investors, including ventures capital firms focused on biotechnology, but has not indicated any timeline for going public. The CRISPR and gene editing space has attracted significant investor interest, with several companies in this sector successfully going public in recent years. However, there are no confirmed details about Mammoth Biosciences' current valuation, recent funding activities, or discussions about IPO timing. As a biotech company developing cutting-edge technology, Mammoth would likely need to advance its platforms through clinical development and demonstrate significant commercial potential before considering public markets.
Competitors
Frequently Asked Questions
Does Mammoth Biosciences have a stock?
No, Mammoth Biosciences has not had an IPO and remains privately held. The company has not announced any plans to go public.
When is the Mammoth Biosciences IPO date?
Mammoth Biosciences has not announced an IPO date, and there are no confirmed details about when the company might consider going public. Any timeline remains highly speculative.
How can I buy Mammoth Biosciences stock?
Mammoth Biosciences stock is not available for purchase as the company is privately held. If the company eventually goes public, shares would become available through standard brokerage platforms.
Stay Updated on the Mammoth Biosciences IPO
Get real-time alerts when Mammoth Biosciences files for an IPO, prices shares, or begins trading.
Get IPO Alerts